AI companies including Anthropic, Nvidia, and Google's Isomorphic Labs are increasingly investing in health care and drug discovery to counter public backlash over data centers and job losses, with Nv…
Chai Discovery, a San Francisco-based AI drug discovery company whose platform is used by Eli Lilly, Pfizer, and Novartis, is hiring a Scientist for Protein Design to work on-site with its science tea…
Northeastern University graduate students found that popular open-source AI frameworks, including GPT Researcher and Agent Laboratory, are not yet capable of replacing human researchers in drug discov…
Chai Discovery, a San Francisco-based company building AI models for biochemical structure and interaction, posted an internship listing despite stating it does not offer internships, inviting interes…
Chai Discovery, a San Francisco-based biotech startup, released Chai-3, a generative AI model for molecular design that doubles the success rate of its predecessor in creating therapeutic antibodies, …
Invenio Imaging, a San Jose medical-device maker, has completed enrollment in its ON-SITE study of 1,006 patients across seven U.S. medical centers to evaluate its AI-based NIO Lung Cancer Reveal syst…
Isomorphic Labs, the Alphabet spinoff, released IsoDDE on February 10, a unified drug design engine that achieves a 50% success rate on the hardest molecular prediction tasks, outperforming AlphaFold …
Novartis CEO Vas Narasimhan said AI is helping speed up drug discovery timelines, as the pharma giant reported second-quarter earnings that topped estimates. Novartis stock rose Tuesday after the earn…
Chai Discovery Inc. has raised $400 million in Series C funding, nearly tripling its valuation to $3.8 billion, as the AI drug discovery company signs licensing agreements with Pfizer Inc., Eli Lilly …
Google DeepMind and Isomorphic Labs have announced a joint initiative on bioresilience, using AI to predict and defend against biological threats, building on AlphaFold technology. Isomorphic Labs, fo…
Chai Discovery raised $400 million in a Series C round led by Index Ventures, tripling its valuation to $3.8 billion in seven months as the AI drug discovery startup's generative models are deployed a…
Chai Discovery raised $400 million in a Series C round, tripling its valuation to $3.8 billion in seven months, after securing a deal with Novartis. The OpenAI-backed AI drug discovery company's rapid…
Chai Discovery has raised $400 million in a Series C round at a $3.8 billion valuation, tripling its valuation in seven months. The OpenAI-backed drug discovery startup, founded in 2024, builds AI mod…
Anthropic launched its own drug discovery programs targeting neglected diseases that Big Pharma deems unprofitable. Novartis CEO Vas Narasimhan noted AI could cut development time from twelve to seven…
Anthropic CEO Dario Amodei tempered expectations for AI-driven scientific breakthroughs at the company's 'The Briefing: AI for Science' event, suggesting the 'compressed 21st century' he predicted mig…
Isomorphic Labs, a Google DeepMind spinoff, has developed a new AI system called the Isomorphic Drug Design Engine (IsoDDE) to identify hidden binding sites on proteins that standard models like Alpha…